Pathos AI signed a large licensing package with China’s Alphamab Oncology for an additional TROP2/HER3 bispecific ADC and separately aligned with AstraZeneca on a protein degrader from AstraZeneca’s pipeline. The deals add new oncology assets as Pathos continues to build its preclinical portfolio using AI-enabled development and partner-derived molecules.